Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPT NASDAQ:AQST NASDAQ:DYN NASDAQ:MESO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.82-8.0%$12.22$3.98▼$14.48$2.12B1.931.83 million shs1.72 million shsAQSTAquestive Therapeutics$5.42+4.2%$4.31$2.12▼$6.00$518.56M1.823.37 million shs1.90 million shsDYNDyne Therapeutics$13.17-0.2%$11.94$6.36▼$36.09$1.88B1.12.29 million shs2.45 million shsMESOMesoblast$16.26-0.3%$15.30$6.86▼$22.00$2.09B2.26313,023 shs172,850 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-0.07%+7.90%+7.15%+16.28%+227.00%AQSTAquestive Therapeutics+0.58%+6.78%+30.65%+60.00%+6.56%DYNDyne Therapeutics-1.86%+1.54%+4.85%+26.58%-61.91%MESOMesoblast-3.20%+4.55%+3.16%+54.60%+141.99%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$12.82-8.0%$12.22$3.98▼$14.48$2.12B1.931.83 million shs1.72 million shsAQSTAquestive Therapeutics$5.42+4.2%$4.31$2.12▼$6.00$518.56M1.823.37 million shs1.90 million shsDYNDyne Therapeutics$13.17-0.2%$11.94$6.36▼$36.09$1.88B1.12.29 million shs2.45 million shsMESOMesoblast$16.26-0.3%$15.30$6.86▼$22.00$2.09B2.26313,023 shs172,850 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-0.07%+7.90%+7.15%+16.28%+227.00%AQSTAquestive Therapeutics+0.58%+6.78%+30.65%+60.00%+6.56%DYNDyne Therapeutics-1.86%+1.54%+4.85%+26.58%-61.91%MESOMesoblast-3.20%+4.55%+3.16%+54.60%+141.99%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 2.88Moderate Buy$12.38-3.47% DownsideAQSTAquestive Therapeutics 3.00Buy$10.2989.77% UpsideDYNDyne Therapeutics 3.06Buy$34.07158.67% UpsideMESOMesoblast 3.25Buy$24.0047.60% UpsideCurrent Analyst Ratings BreakdownLatest AQST, ADPT, MESO, and DYN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025AQSTAquestive TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$7.00 ➝ $8.009/3/2025AQSTAquestive TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/25/2025DYNDyne TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeOutperform ➝ Strong-Buy$31.00 ➝ $35.008/13/2025AQSTAquestive TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold8/6/2025ADPTAdaptive BiotechnologiesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$10.00 ➝ $14.008/6/2025ADPTAdaptive BiotechnologiesTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$13.00 ➝ $15.008/6/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$13.00 ➝ $15.008/6/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$34.00 ➝ $13.008/5/2025MESOMesoblastCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/31/2025DYNDyne TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$66.00 ➝ $36.007/29/2025DYNDyne TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$25.00 ➝ $23.00(Data available from 9/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M10.91N/AN/A$1.37 per share9.36AQSTAquestive Therapeutics$57.56M9.39N/AN/A($0.66) per share-8.21DYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/AMESOMesoblast$17.20M121.00N/AN/A$4.67 per share3.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$0.82N/AN/AN/A-59.07%-60.93%-23.03%11/6/2025 (Estimated)AQSTAquestive Therapeutics-$44.14M-$0.70N/AN/AN/A-147.38%N/A-63.87%11/3/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)MESOMesoblast-$102.14MN/A0.00N/AN/AN/AN/AN/AN/ALatest AQST, ADPT, MESO, and DYN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025AQSTAquestive Therapeutics-$0.18-$0.14+$0.04-$0.14$11.32 million$10.00 million8/5/2025Q2 2025ADPTAdaptive Biotechnologies-$0.24-$0.17+$0.07-$0.17$49.40 million$49.94 million7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AAQSTAquestive TherapeuticsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AMESOMesoblastN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.842.75AQSTAquestive TherapeuticsN/A3.533.18DYNDyne Therapeutics0.1716.8316.83MESOMesoblast0.111.991.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%AQSTAquestive Therapeutics32.45%DYNDyne Therapeutics96.68%MESOMesoblast1.43%Insider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.40%AQSTAquestive Therapeutics8.35%DYNDyne Therapeutics14.14%MESOMesoblast18.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790152.27 million142.53 millionOptionableAQSTAquestive Therapeutics16099.72 million91.40 millionOptionableDYNDyne Therapeutics100142.26 million122.15 millionOptionableMESOMesoblast80128.00 million103.93 millionOptionableAQST, ADPT, MESO, and DYN HeadlinesRecent News About These Companies3 ASX 200 stocks racing higher in this week's falling marketSeptember 19, 2025 | msn.com257,143 Shares in Mesoblast Limited $MESO Purchased by Goldman Sachs Group Inc.September 19, 2025 | marketbeat.comSayona, Mesoblast, Mader: All the biggest ASX director trades from the last weekSeptember 19, 2025 | msn.comMesoblast (NASDAQ:MESO) Shares Gap Up - Still a Buy?September 16, 2025 | marketbeat.comSuccessful Commercial Launch of Ryoncil® Highlighted at Global Healthcare ConferencesSeptember 14, 2025 | globenewswire.comMesoblast (NASDAQ:MESO) Shares Gap Down - Time to Sell?September 14, 2025 | marketbeat.comMesoblast Limited $MESO Shares Acquired by Cubist Systematic Strategies LLCSeptember 12, 2025 | marketbeat.comMesoblast shares lift following $76m convertible note agreementsSeptember 5, 2025 | msn.comHotCopper Trends: Mesoblast raising $50M; Larvotto hits & Alterity HaltSeptember 4, 2025 | msn.comMesoblast Secures Option for $50 Million Convertible Notes to Bolster GrowthSeptember 4, 2025 | msn.comMesoblast Enters Into Option To Issue US$50 Million Convertible NotesSeptember 3, 2025 | globenewswire.comMesoblast Limited (NASDAQ:MESO) Given Consensus Rating of "Buy" by BrokeragesSeptember 3, 2025 | marketbeat.comMesoblast Limited (NASDAQ:MESO) Q4 2025 Earnings Call TranscriptSeptember 2, 2025 | insidermonkey.comMesoblast (NASDAQ:MESO) Shares Gap Down - Should You Sell?August 31, 2025 | marketbeat.comMesoblast Full Year 2025 Earnings: Misses ExpectationsAugust 29, 2025 | finance.yahoo.comMesoblast Limited 2025 Q4 - Results - Earnings Call PresentationAugust 29, 2025 | seekingalpha.comBanner Year for Mesoblast With First FDA Product Approval and Successful Commercial Launch of Ryoncil®August 28, 2025 | globenewswire.comExamining the Future: Mesoblast's Earnings OutlookAugust 27, 2025 | benzinga.comExamining the Future: Mesoblast's Earnings OutlookAugust 27, 2025 | benzinga.comMESO | Mesoblast Ltd. ADR Annual Income Statement | MarketWatchAugust 14, 2025 | marketwatch.comUlcerative Colitis Treatment Landscape Undergoes Rapid Transformation with FDA Approvals and Robust Pipeline | DelveInsightAugust 13, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAQST, ADPT, MESO, and DYN Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$12.82 -1.11 (-7.97%) Closing price 04:00 PM EasternExtended Trading$12.92 +0.10 (+0.78%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Aquestive Therapeutics NASDAQ:AQST$5.42 +0.22 (+4.23%) Closing price 04:00 PM EasternExtended Trading$5.41 -0.01 (-0.18%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Dyne Therapeutics NASDAQ:DYN$13.17 -0.02 (-0.15%) Closing price 04:00 PM EasternExtended Trading$13.16 -0.01 (-0.08%) As of 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Mesoblast NASDAQ:MESO$16.26 -0.05 (-0.31%) Closing price 04:00 PM EasternExtended Trading$16.27 +0.01 (+0.09%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm’s RSI Just Hit Its High of the Year—Why That’s Bullish 2 Ways to Trade Amazon Ahead of October’s Prime Day AutoZone Pulls Into a Buy-the-Dip Opportunity Rocket Lab’s Bullish Case Remains Intact Despite Recent Offering Broadcom Price Targets Just Reached Above $400 for the First Time Replace Your Fixed Income With This Dividend ETF These 3 Mega-Cap Giants Just Increased Dividends by 7% or More Ford Set to Outpace GM With Tariff Tailwinds and EPS Momentum Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
